Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy
PUBLICATION: Ann Surg Oncol (2016) 23: 1522. https://doi.org/10.1245/s10434-015-5030-1. AUTHORS: Paul Read More
Equivalence of MammaPrint Array Types in Clinical Trials and Diagnostics
PUBLICATION: Breast Cancer Res Treat (2016) 156: 279. https://doi.org/10.1007/s10549-016-3764-5 AUTHORS: Read More
Molecular Subtyping Improves Diagnostic Stratification of Patients with Primary Breast Cancer into Prognostically-Defined Risk Groups
PUBLICATION: Breast Cancer Res Treat (2015) 154: 81. https://doi.org/10.1007/s10549-015-3587-9. AUTHORS: Read More
Application of a 70-Gene Expression Profile to Japanese Breast Cancer Patients
PUBLICATION: Breast Care 2015;10:118-122 https://doi.org/10.1159/000376562. AUTHORS: Shimizu H., Horimoto Y., Read More
Gene Expression Profiling to Predict the Risk of Locoregional Recurrence in Breast Cancer: A Pooled Analysis
PUBLICATION: Breast Cancer Res Treat (2014) 148: 599. https://doi.org/10.1007/s10549-014-3188-z. AUTHORS: Read More
Genomic Profile of Breast Cancer: Cost-Effectiveness Analysis from the Spanish National Healthcare System Perspective
PUBLICATION: Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):889-99. doi: 10.1586/14737167.2014.957185. Read More
Molecular Subtyping Predicts Pathologic Tumor Response in Early-Stage Breast Cancer Treated with Neoadjuvant Docetaxel Plus Capecitabine with or without Trastuzumab Chemotherapy GalleryMolecular Subtyping Predicts Pathologic Tumor Response in Early-Stage Breast Cancer Treated with Neoadjuvant Docetaxel Plus Capecitabine with or without Trastuzumab Chemotherapy
Molecular Subtyping Predicts Pathologic Tumor Response in Early-Stage Breast Cancer Treated with Neoadjuvant Docetaxel Plus Capecitabine with or without Trastuzumab Chemotherapy
PUBLICATION: Med Oncol. (2014) 31: 163. https://doi.org/10.1007/s12032-014-0163-9. AUTHORS: Soley Bayraktar, Read More
The Multigene Signature MammaPrint Impacts on Multidisciplinary Team Decisions in ER+, HER2− Early Breast Cancer
PUBLICATION: British Journal of Cancer, volume 111, pages 837–842 (26 Read More
Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) GalleryChemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)
Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)
PUBLICATION: Annals of Surgical Oncology; October 2014, Volume 21, Issue Read More
European Inter-Institutional Impact Study of MammaPrint
PUBLICATION: The Breast August 2014, Volume 23, Issue 4, Pages Read More
